Otonomy Appoints Anthony J. Yost Chief Commercial Officer

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Otonomy Appoints Anthony J. Yost Chief Commercial Officer

SAN DIEGO, Oct. 21, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC ), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the appointment of Anthony J. Yost as chief commercial officer. Mr. Yost brings 30 years of experience in pharmaceutical product sales and marketing that includes building and managing commercial teams at multiple companies.

"The addition of Tony to the Otonomy team is an important step in the establishment of our commercial organization as we prepare for the regulatory filing of the New Drug Application for AuriPro™ with the FDA in the first half of 2015," said David A. Weber, Ph.D., president and CEO of Otonomy. "Tony's expertise in building high-performance commercial teams, and his broad pharmaceutical sales and marketing experience, including products sold in the hospital setting, as well as physician-administered drugs, make him well-suited to lead the commercialization efforts for AuriPro and Otonomy's other product candidates."

Mr. Yost has a strong track record in developing and implementing successful commercialization strategies in the life science industry including repeat experience in building and managing sales and marketing teams, and launching more than 20 new products. He joins Otonomy after serving as chief commercial officer for specialty pharmaceutical companies Prometheus Laboratories and EKR Therapeutics. Previously he served as general manager for the Western U.S. Operating Unit of Novartis Pharmaceuticals where he led commercial operations totaling more than 600 employees generating annual revenues in excess of $600 million. Mr. Yost joined Novartis after serving as president of Innovex, the U.S.-based pharmaceutical sales and marketing services division of Quintiles Transnational. At Innovex, he was responsible for more than 2,000 employees providing commercial services for both large and small pharmaceutical clients across a broad range of therapeutic areas. Mr. Yost has also held various commercial and general management positions at Schering-Plough, Boehringer Mannheim Pharmaceuticals and Eli Lilly and Company. He received a Bachelor of Science in Pharmacy from Purdue University.

About Otonomy

Otonomy is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic (IT) injection. Otonomy has three product candidates in development. AuriPro™ is an antibiotic that has completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. OTO-104 is a steroid that is in the first of two pivotal clinical studies for the treatment of patients with Ménière's disease. OTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For additional information, please visit www.otonomy.com .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements concerning the regulatory filing of the New Drug Application for AuriPro™ with the FDA in the first half of 2015. Forward-looking statements reflect the Company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the risk that clinical drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus filed on August 13, 2014. The Company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.

Media Inquiries Canale Communications Heidi Chokeir, Ph.D. Vice President 619.849.5377 Investor Inquiries Westwicke Partners Robert H. Uhl Managing Director 858.356.5932

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 5

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 174

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 47

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Cavalry’s I-70 Towing Bet Starts With Columbus Base

Updated Category News Views 71

A jackknifed tractor-trailer does not care about a private-equity playbook. It needs the right rig, a trained crew and somebody arriving before a blocked highway turns into an all-day mess. That unglamorous reality is exactly why Southfield Capital’s new Cavalry Fleet Services platform deserves a closer look. Commercial towing is a necessary, hard-edged local business...

Continue Reading
ISDN Holdings: Leading APAC Automation with Innovation

Updated Category News Views 81

Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 138

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 157

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 25

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading

Top 5 Most Recently Viewed Articles

Kering Faces Challenges as Goldman Sachs Downgrades Rating

Updated Category News Views 108

Kering's stock price took a serious hit back in early 2024 after Goldman Sachs slapped a "sell" rating on the luxury group's shares. At the time, they were sitting at €249.50, reflecting a sharp decline of about 2.9%. Desks were buzzing over this downgrade, particularly because it pointed fingers at Gucci—a brand that's been Kering’s cash cow for years. Kering's...

Continue Reading
Treatment.com AI to Showcase Innovations at Cantech Conference

Updated Category News Views 174

Treatment.com AI, a player in healthcare tech, geared up for its big moment at the Cantech Letter Investment Conference back in 2024. The spotlight was on Dr. Essam Hamza, CEO of the firm, who was set to reveal how their advanced AI-driven solutions were set to transform patient care. You could almost hear traders buzzing about the potential impact on share prices as the...

Continue Reading
Bombardier Celebrates First Challenger 3500 Deliveries

Updated Category News Views 408

Landmark Deliveries of the Challenger 3500 Bombardier proudly announces a significant achievement with the beginning of deliveries of three state-of-the-art Challenger 3500 aircraft to Aloula Aviation. This event marks a milestone as these are the first Challenger 3500 aircraft registered in Saudi Arabia, showcasing Bombardier's dedication to enhancing global aviation....

Continue Reading
Siili Solutions Shares Repurchase Update for 2025

Updated Category News Views 167

Overview of Siili Solutions Plc's Share Repurchase Siili Solutions Plc is taking significant steps to enhance shareholder value through strategic share buybacks. Recently, they announced a share repurchase on June 26, 2025, which adds to their ongoing efforts in the market. This initiative is an essential part of their financial strategy, showing a commitment to returning...

Continue Reading
Xiaomi's YU7 SUV Surpasses Tesla Model Y in China Sales

Updated Category News Views 236

Xiaomi's YU7 SUV Emerges as a Strong Contender Xiaomi Corp. has made a significant impact in the electric vehicle sector, particularly in January when their YU7 SUV surpassed Tesla Inc.'s Model Y in sales within the Chinese market. The impressive sales figures highlight Xiaomi's growing influence in the automotive landscape. Strong Sales Performance of the YU7 During the...

Continue Reading